Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity that Associates with a Clinically Aggressive Subtype of Prostate Cancer

By sjmartinez • March 11, 2025

Zhang L, Teng PC, Cavassani KA, Wang J, Grasso C, Watson J, Chen Z, Tu KH, Salumbides B, Rohena-Rivera K, Gevorkian L, Kim M, You S, Di Vizio D, Sandler HM, Daskivich T, Bhowmick NA, Freeman MR, Tseng HR, Chen JF, Posadas EM. Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity that Associates with a Clinically Aggressive Subtype of Prostate Cancer. Clin Cancer Res. 2025 Mar 10. doi: 10.1158/1078-0432.CCR-24-3660. Epub ahead of print. PMID: 40063516.

Tags: Cedars Sinai DoM, Hematology/Oncology, Publications

Design and Rationale of the WARRIOR Ancillary Study for Coronary CT Angiographic Analysis

Tamarappoo B, Wolny R, Tomasino GF, Berman D, Handberg E, Pepine CJ, Lo MC, Budoff M, Shaw L, Shufelt C, Wei J, Gulati M, Merz[...]

Public Health

Tan ZS, Qureshi N, Sicotte N, Escovedo C, Hirsch A, Afrashteh A, Miles PB, Roberts P. Public Health. Alzheimers Dement. 2025 Dec;21 Suppl 6(Suppl 6):e101651.[...]

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions

Patil T, Lin JJ, Cheema PK, Carrizosa DR, Burkard ME, Elamin YY, Desai J, Patel JD, Nagasaka M, Reckamp KL, Waqar SN, Bauman JR, Schram[...]